Photodynamic Therapy Is an Effective Adjuvant Therapy for Image-Guided Surgery in Prostate Cancer

Wang, Xinning; Ramamurthy, Gopolakrishnan; Shirke, Aditi; Walker, Ethan; Mangadlao, Joey Dacula; Wang, Ziying; Wang, Yu; Shan, Lingpeng; Schluchter, Mark D.; Dong, Zhipeng; Brady‐Kalnay, Susann M.; Walker, Natalie; Gargesha, Madhusudhana; MacLennan, Gregory T.; Luo, Dong Hua; Sun, Rongcan; Scott, Bryan; Roy, Debashish; Li, Jing; Basilion, James P.

doi:10.1158/0008-5472.can-19-0201

Cited by 39 publications

(30 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another study, Doeveren et al used adjuvant meta -tetrahydroxyphenylchlorin-mediated PDT in patients with a malignancy in the head and neck with close or positive resection margins who were not eligible for conventional treatment modalities and they reported that PDT could be applied as adjuvant therapy after surgery ( van Doeveren et al, 2018 ). Wang et al recently proposed that in prostate cancer, PDT might be an effective adjuvant therapy for image-guided surgery ( Wang X. et al, 2020 ). Friedberg et al reported that Foscan mediated PDT may be safely combined with surgery at the established maximally tolerated dose ( Friedberg et al, 2003 ).…”

Section: Photodynamic Therapy Combined With Other Therapy Modalitiesmentioning

confidence: 99%

Photodynamic Therapy for the Treatment and Diagnosis of Cancer–A Review of the Current Clinical Status

2021

View full text Add to dashboard Cite

Photodynamic therapy (PDT) has been used as an anti-tumor treatment method for a long time and photosensitizers (PS) can be used in various types of tumors. Originally, light is an effective tool that has been used in the treatment of diseases for ages. The effects of combination of specific dyes with light illumination was demonstrated at the beginning of 20th century and novel PDT approaches have been developed ever since. Main strategies of current studies are to reduce off-target effects and improve pharmacokinetic properties. Given the high interest and vast literature about the topic, approval of PDT as the first drug/device combination by the FDA should come as no surprise. PDT consists of two stages of treatment, combining light energy with a PS in order to destruct tumor cells after activation by light. In general, PDT has fewer side effects and toxicity than chemotherapy and/or radiotherapy. In addition to the purpose of treatment, several types of PSs can be used for diagnostic purposes for tumors. Such approaches are called photodynamic diagnosis (PDD). In this Review, we provide a general overview of the clinical applications of PDT in cancer, including the diagnostic and therapeutic approaches. Assessment of PDT therapeutic efficacy in the clinic will be discussed, since identifying predictors to determine the response to treatment is crucial. In addition, examples of PDT in various types of tumors will be discussed. Furthermore, combination of PDT with other therapy modalities such as chemotherapy, radiotherapy, surgery and immunotherapy will be emphasized, since such approaches seem to be promising in terms of enhancing effectiveness against tumor. The combination of PDT with other treatments may yield better results than by single treatments. Moreover, the utilization of lower doses in a combination therapy setting may cause less side effects and better results than single therapy. A better understanding of the effectiveness of PDT in a combination setting in the clinic as well as the optimization of such complex multimodal treatments may expand the clinical applications of PDT.

show abstract

Section: Photodynamic Therapy Combined With Other Therapy Modalitiesmentioning

confidence: 99%

Photodynamic Therapy for the Treatment and Diagnosis of Cancer–A Review of the Current Clinical Status

2021

View full text Add to dashboard Cite

show abstract

“…Thus, PDT is a multiple-targeting method. Since the US Food and Drug Administration listed PDT as a new treatment method for the clinical treatment of cancer patients[ 3 ], alone or combined with surgery[ 4 ] and/or chemotherapy[ 5 ], PDT has been applied in large numbers worldwide. For PDT treatment, some Western countries have established relatively systematic treatment plans[ 6 - 8 ].…”

Section: Introductionmentioning

confidence: 99%

Photodynamic therapy regulates fate of cancer stem cells through reactive oxygen species

Zhang

Wang

et al. 2020

WJSC

View full text Add to dashboard Cite

Photodynamic therapy (PDT) is an effective and promising cancer treatment. PDT directly generates reactive oxygen species (ROS) through photochemical reactions. This oxygen-dependent exogenous ROS has anti-cancer stem cell (CSC) effect. In addition, PDT may also increase ROS production by altering metabolism, endoplasmic reticulum stress, or potential of mitochondrial membrane. It is known that the half-life of ROS in PDT is short, with high reactivity and limited diffusion distance. Therefore, the main targeting position of PDT is often the subcellular localization of photosensitizers, which is helpful for us to explain how PDT affects CSC characteristics, including differentiation, self-renewal, apoptosis, autophagy, and immunogenicity. Broadly speaking, excess ROS will damage the redox system and cause oxidative damage to molecules such as DNA, change mitochondrial permeability, activate unfolded protein response, autophagy, and CSC resting state. Therefore, understanding the molecular mechanism by which ROS affect CSCs is beneficial to improve the efficiency of PDT and prevent tumor recurrence and metastasis. In this article, we review the effects of two types of photochemical reactions on PDT, the metabolic processes, and the biological effects of ROS in different subcellular locations on CSCs.

show abstract

“…Orthotopic PC3pipGFP prostate cancer models were established as previously described using green fluorescence protein (GFP) transfected PC3pip cells 59 . Mice bearing orthotopic PC3pipGFP tumors were injected with 100 nmol/kg of PSMA-1-MMAE-IR700.…”

Section: Methodsmentioning

confidence: 99%

“…68 Ga-PSMA11 and 18 F-labeled Pylarify have been approved by Food and Drug Administration (FDA) for positron emission tomography (PET) imaging of prostate cancer. We have successfully developed a high affinity PSMA ligand (PSMA-1) 57 , and have utilized it to develop PSMA-targeted PDT agents 58 , 59 . Although our PSMA-targeted PDT conjugates showed effective tumor inhibition, some cancer cells were found to survive and tumor recurrences were eventually seen in immunocompromised mouse models after PDT treatment 58 .…”

Section: Introductionmentioning

confidence: 99%

A low molecular weight multifunctional theranostic molecule for the treatment of prostate cancer

Wang¹,

Sun²,

Wang³

et al. 2022

Theranostics

Self Cite

View full text Add to dashboard Cite

Rationale: Although surgery and radiation therapy in patients with low risk prostate cancer appear appropriate and effective, those with high-risk localized disease almost always become hormone refractory and then rapidly progress. A new treatment strategy is urgently needed for patients with high-risk localized prostate cancer, particularly an approach that combines two drugs with different mechanisms. Combinations of photodynamic therapy (PDT) and chemotherapy have shown synergistic effects in clinical trials, but are limited by off-target toxicity. Prostate specific membrane antigen (PSMA) is a well-established biomarker for prostate cancer. Here we describe the use of a PSMA ligand to selectively and simultaneously deliver a potent microtubule inhibiting agent, monomethyl auristatin E (MMAE), and a PDT agent, IR700, to prostate cancers. Methods: Using a bifunctional PSMA ligand PSMA-1-Cys-C6-Lys, we created a novel theranostic molecule PSMA-1-MMAE-IR700. The molecule was tested in vitro and in vivo for selectivity and antitumor activity studies. Results: PSMA-1-MMAE-IR700 showed selective and specific uptake in PSMA-positive PC3pip cells, but not in PSMA-negative PC3flu cells both in vitro and in vivo . In in vitro cytotoxicity studies, when exposed to 690 nm light, PSMA-1-MMAE-IR700 demonstrated a synergistic effect leading to greater cytotoxicity for PC3pip cells when compared to PSMA-1-IR700 with light irradiation or PSMA-1-MMAE-IR700 without light irradiation. In vivo antitumor activity studies further showed that PSMA-1-MMAE-IR700 with light irradiation significantly inhibited PC3pip tumor growth and prolonged survival time as compared to mice receiving an equimolar amount of PSMA-1-IR700 with light irradiation or PSMA-1-IR700-MMAE without light irradiation. Conclusion: We have synthesized a new multifunctional theranostic molecule that combines imaging, chemotherapy, and PDT for therapy against PSMA-expressing cancer tissues. This work may provide a new treatment option for advanced prostate cancer.

show abstract

Photodynamic Therapy Is an Effective Adjuvant Therapy for Image-Guided Surgery in Prostate Cancer

Cited by 39 publications

References 21 publications

Photodynamic Therapy for the Treatment and Diagnosis of Cancer–A Review of the Current Clinical Status

Photodynamic Therapy for the Treatment and Diagnosis of Cancer–A Review of the Current Clinical Status

Photodynamic therapy regulates fate of cancer stem cells through reactive oxygen species

A low molecular weight multifunctional theranostic molecule for the treatment of prostate cancer

Contact Info

Product

Resources

About